< Back to latest news & events

Event

LSPN North America 2023

August 2023

HGF are gold sponsors of the LSPN North America Fall event, due to go ahead in San Francisco from 10th-11th October 2023.

This two day event will focus on the latest regulatory developments in the life sciences. You will gain insight into the sector issues of importance and listen to industry experts share their views. This event will be interactive so you can take part in smaller discussion groups to share opinions and views on different topics. You will have the opportunity to put questions to the speakers and panelists, whilst also networking with other IP professionals.

HGF Partner and Patent Attorney, Andrew Camenisch and Patent Director, Punita Shah will be speaking at the event on ‘European IP landscape – (1) the latest Enlarged Board of Appeal decision and (2) the UPC in the “cold light of day”’.

Here is the synopsis of Andrew and Punita’s speech:

“In March this year, Europe saw dawn of the Unified Patent Court and the issuance of the England Board of Appeal Decision relating to the use of post-published evidence to support inventive step.

In their presentation, Andy and Punita will discuss how Europe’s patenting and litigation landscape is changing as the first set of orders and cases before the UPC emerge. The talk will highlight emerging trends in the use of the UPC, and lessons we can learn from early users of the new system.

The concept of plausibility has caused great controversy in European patent law in recent years. The issuance of the Enlarged Board of Appeal decision was eagerly awaited, in the hope that it would bring clarity to this issue. Andy and Punita will discuss the impact of the decision, and whether it does in fact bring any legal certainty to the issue of plausibility in Europe.”

Patent Director, Ellie Purnell will also be attending the event.

The full agenda for the event can be viewed here.

Click the button below to find out more and register:

Latest updates

Polymorphs: Clearing the Inventive Step Hurdle at the European Patent Office (EPO)

Polymorphic forms of active pharmaceutical ingredients (APIs) can represent commercially valuable compound subject matter and can be critical to providing necessary drug product characteristics and performance. However, patenting polymorphs is …

Read article

IQPC Global US Exchange

HGF are proud ‘Silver Plus’ sponsors of the IQPC Global US Exchange, at the Austin Marriot South, Texas. The IQPC Global US Exchange will be held at the Austin Marriot …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Court of Appeal Decision Upholds Invalidity of Patent Due to Amendment Identifying Embodiment as Outside the Scope of the Claims

In a case that highlights the challenges arising due to post-grant amendments, and in particular interpretation of the claims in view of the description, the Court of Appeal in Ensygnia …

Read article

UPC Court of Appeal clarifies approach for interpreting claims with “obvious” errors

Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. [UPC_CoA_402/2024] –Court of Appeal of the UPC (Grabinski, Blok, Gougé, Enderlin, Hedberg) – 20 December 2024 Alexion Pharmaceuticals, Inc. v Amgen Technology …

Read article

IP Ingredients: Winter Case Law Review 2024

As the nights draw in and the frenzy to finish everything off before the holiday season reaches its peak, it’s time to take a break, grab your favourite hot beverage …

Read article